Michael Ludwig, MS, PhD - Multiple Sclerosis (2017 Conference) (LDN, low dose naltrexone)
In this presentation Michael Ludwig discusses how the OGF-OGFr access can be modulated to alter cell proliferation? And the answer is by opioid antagonists. Naltrexone is a non-selective opioid receptor, meaning that it blocks all classical opioid receptors as well as GFR. He explains the role of Low Dose Naltrexone (LDN) and how it works for Multiple Sclerosis MS.
Thank you for listening to this presentation. All past conference presentations can be found on our website https://ldnresearchtrust.org/ldn-conferences